NLM Digital Collections

Search

Start Over Subjects Humans ✖Remove constraint Subjects: Humans Subjects Opiate Substitution Treatment ✖Remove constraint Subjects: Opiate Substitution Treatment Subjects Opioid-Related Disorders -- drug therapy ✖Remove constraint Subjects: Opioid-Related Disorders -- drug therapy

1. The role of community health centers in addressing the opioid epidemic

Author(s):
Zur, Julia, author
Tolbert, Jennifer, author
Sharac, Jessica, author
Markus, Anne, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, July 2018
Subject(s):
Community Health Centers -- statistics & numerical data
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Drug Overdose -- epidemiology
Inservice Training
Medicaid
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment
Practice Patterns, Physicians'
Prescription Drug Misuse -- statistics & numerical data
State Government
Humans
United States

2. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

3. Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, October 2017
Subject(s):
Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Outcome Assessment (Health Care)
Community-Institutional Relations
Buprenorphine -- therapeutic use
Inservice Training
Insurance Coverage
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Prescription Drug Diversion -- prevention & control
Humans
United States
United States. Department of Health and Human Services.

4. Why health plans should go to the "MAT" in the fight against opioid addiction

Author(s):
Elitzer, Julia, author
Tatar, Margaret, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, September 2017
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Cost Savings
Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Care Costs
Health Services Accessibility
Healthcare Disparities
Inappropriate Prescribing -- prevention & control
Insurance Coverage -- legislation & jurisprudence
Managed Care Programs
Medicaid
Mental Health Services -- legislation & jurisprudence
Methadone -- therapeutic use
Naloxone
Naltrexone -- therapeutic use
Neonatal Abstinence Syndrome -- drug therapy
Opioid-Related Disorders -- epidemiology
Patient Care Management
Prescription Drug Diversion
State Government
Humans
California
United States

5. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, February 2019
Subject(s):
Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
Buprenorphine -- administration & dosage
Clinical Trials as Topic
Delayed-Action Preparations
Narcotic Antagonists
Opiate Substitution Treatment
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

6. Opioid use decreased in Medicare Part D, while medication-assisted treatment increased

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2019
Subject(s):
Analgesics, Opioid -- therapeutic use
Medicare Part D
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Overdose -- drug therapy
Drug Utilization -- trends
Forecasting
Inappropriate Prescribing
Naloxone -- therapeutic use
State Government
Humans
United States

7. MAT in the emergency department: FAQ

Author(s):
Newman, Sandra, author
Publication:
[Oakland, California] : California Health Care Foundation, March 2019
Subject(s):
Emergency Medical Services
Emergency Service, Hospital
Insurance, Health, Reimbursement
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Substance-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Inservice Training
Methadone -- therapeutic use
State Government
Telemedicine
Humans
California
United States

8. MAT for hospitalized patients

Author(s):
Newman, Sandra, author
Publication:
[Oakland, California] : California Health Care Foundation, June 2019
Subject(s):
Hospitalization
Inpatients
Insurance, Health, Reimbursement
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Drug Costs
Hospital Costs
Methadone -- therapeutic use
Reimbursement Mechanisms
State Government
Humans
California
United States